First published: 27th February 2024
Cumulus Neuroscience will present validation data on two novel assessments of cognitive impairment at the AD/PD™ 2024 in Lisbon, Portugal.
Titled "Technical and Clinical Validation of Novel Cognitive Tests for Remote Sampling of Memory and Executive Function,” the poster was accepted by the AD/PD Scientific Program Committee.
“Tools that enable this type of measurement have the potential to enable earlier detection of disease and help biopharma companies streamline clinical trial designs.”
Brian Murphy, Ph.D.
CSO, Cumulus Neuroscience
“Frequent, repeated samples of validated measures of cognitive assessments can be aggregated to increase the precision with which we measure diseases including Alzheimer’s,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Tools that enable this type of measurement have the potential to enable earlier detection of disease and help biopharma companies streamline clinical trial designs. We look forward to sharing data from two technical validation studies at AD/PD.”
Cumulus poster presentation details are as follows:
Title: Technical and Clinical Validation of Novel Cognitive Tests for Remote Sampling of Memory and Executive Function
Poster Number: Shift 1, Poster #0248
Theme A: B-Amyloid Diseases / A04.I. Imaging, Biomarkers, Diagnostics: Cognitive, Psychometric & Behavioral Tests, Digital Endpoints, Remote Testing
Dates & Times:- 10:40 - 11:10 AM
- 12:50 - 14:30 PM
- 16:30 - 17:00 PM
- 10:40 - 11:10 AM
- 12:50 - 13:50 PM
- 15:50 - 16:20 PM